Objective To identify and analyze the criteria, approaches, and conceptual frameworks, used for national/international priority setting. Data sources We performed a search of the main biomedical databases (Medline/PubMed, Embase, Centre for Reviews and Dissemination, and Cochrane), and we reviewed assessment agency websites, among other sources. Study design An systematic review of the literature was carried out. Data collection Eligibility criteria for inclusion were based on set of predefined criteria. Systematic reviews and/or qualitative studies (interviews, surveys, expert consensus, etc) that aimed to identify prioritization criteria or develop general operational frameworks for the selection of health priorities were included. A critical analysis is made of all the aspects that may be useful for any public body that intends to establish priorities in health. Principal findings We found that there are no standardized criteria for priority setting, although common trends have been identified regarding key elements. Eight key domains were identified: 1) need for intervention; 2) health outcomes; 3) type of benefit of the intervention; 4) economic consequences; 5) existing knowledge on the intervention/quality and uncertainties of the regarding evidence; 6) implementation and complexity of the intervention/feasibility; 7) justice and ethics; and 8) overall context. Conclusions Our review provides a thorough analysis of the relevant issues and offers key recommendations regarding considerations for developing a national prioritization framework. Findings are envisioned to be useful for different public organizations that are aiming to establish healthcare priorities. Electronic supplementary material The online version of this article (10.1186/s40545-019-0181-2) contains supplementary material, which is available to authorized users.

An abbreviated 5-day course of biosimilar filgrastim provided optimal primary prophylaxis against FN post-chemotherapy TAC in patients with breast cancer. The clinical relevance of the highest FN incidence in the lenograstim cohort needs further attention.

Background: The development of nanostructures (nanoparticles and nanocapsules) is one of the most important pipelines of research of pharmaceutical technology. Methods: These nanotechnology pharmaceuticals allow the vectorization of drugs to tissues or cells target, allowing thus actions more specific and therapeutically active directed by molecules. Results: The use of molecules with an affinity for membrane receptors expressed in specific excess in tumor cells, monoclonal antibodies, or proteins, among others, is common for this purpose. In addition, these nanosystems allow to deliver drugs that could be the basis of the pharmacological treatment of many disorders of genetic origin in the future: biomolecules. Conclusion: The future scope of drug vectoring systems to target drug delivery using nanotechnologies can increase the control of pharmacokinetic parameters of chemotherapeutic agents.

No abstract